Sep 2026· European Journal of Haematology· 0 citations· 33 references
Medicine
TL;DR
The data support recent recommendations advising treating patients with tandem transplantation regimes and support the idea that the optimal consolidation strategy remains to be defined.
Abstract
Objectives
Primary plasma cell leukemia (pPCL) is a rare disease with poor outcomes. As data on randomized phase-III trials are lacking, treatment recommendations are predominately based on retrospective analyses incorporating time periods with outdated therapies. Thus, the optimal consolidation strategy remains to be defined.
Methods
We conducted a retrospective, multi-center analysis with 49 transplant-eligible patients diagnosed with pPCL between 2011 and 2025 focusing on different stem cell transplantation (SCT) strategies as consolidation treatment in first remission: single autologous (auto) or single allogeneic (allo) SCT versus patients with tandem cell therapy strategies (auto-auto, allo-auto, auto-chimeric antigen receptor therapy).
Results
The median follow-up after first SCT was 31 months. The cumulative incidence of initiating next treatment was lower after tandem cell therapy compared to single SCT (at 12 months: 42% vs. 57%, p = 0.006). Moreover, in a multivariable analysis incorporating cytogenetic risk and response to induction therapy, tandem transplantation strategies tended to be the only independent predictor for prolonged time to next treatment (TTNT, p = 0.077). Noteworthy, differences in TTNT between patients with a single SCT and patients with tandem cell therapy did not translate into an improved overall survival, possibly due to potent salvage therapies.
Conclusions
Our data support recent recommendations advising treating patients with tandem transplantation regimes.
BACKGROUND
T-cell prolymphocytic leukemia (T-PLL) is a rare, aggressive mature T-cell malignancy with limited therapeutic options. Alemtuzumab remains the backbone of therapy, and fit responders are consolidated with allogeneic stem cell transplantation (alloSCT). However, contemporary population-level outcomes remain...
M. Brink, Arie C. van der Spek, J. Doorduijn et al.· European Journal of Haematol...· 0 citations
Analysis of the short- and long-term outcomes in relation to HDCT regimens revealed the best rates achieved by the LEAM program, however, the multivariate regression analysis excluded the value of HDCT regimens for OS in r/r cHL.
G. Petrova, И. С. Монин, N. Zolotaikina et al.· Clinical oncohematology· 0 citations
Background. Multiple myeloma (MM) remains a chronic hematologic malignancy. However, treatment outcomes have improved significantly due to the introduction of new targeted agents and high-dose therapy with autologous hematopoietic stem cell transplantation (auto-HSCT) into clinical practice. Several researchers have de...
M. Solovev, L. Mendeleeva, M. V. Solov'eva· Oncohematology· 0 citations
The effect of different maintenance therapies on outcome after autologous hematopoietic cell transplantation (AHCT) was analyzed in newly diagnosed multiple myeloma (NDMM) patients using global real-world data. NDMM patients transplanted between 2013 and 2017 were selected from the Worldwide Network for Blood and Marro...
Andrew J. Cowan, L. Gras, R. Cassano et al.· Haematologica· 0 citations
ASCT2 is a feasible salvage strategy in selected Indian patients with multiple myeloma, yielding favorable outcomes with acceptable toxicity, and three patients remain alive and in sustained remission.
Disha Kakkar, Vivek Mohan, Hamza Dalal et al.· Indian Journal of Cancer· 0 citations
Primary and secondary central nervous system lymphomas (PCNSL and SCNSL, respectively) are aggressive non-Hodgkin lymphomas with high relapse risk. Methotrexate rarely achieves durable remission, necessitating combination therapy or consolidation. Although high-dose busulfan and thiotepa (BuTT) conditioning followed by...
Yusuke Higuchi, H. Tatetsu, Taichi Hirano et al.· International journal of hem...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.